Deuterium Isotope Effects on Drug Pharmacokinetics. I. System-Dependent Effects of Specific Deuteration with Aldehyde Oxidase Cleared Drugs

The pharmacokinetic properties of drugs may be altered by kinetic deuterium isotope effects. With specifically deuterated model substrates and drugs metabolized by aldehyde oxidase, we demonstrate how knowledge of the enzyme's reaction mechanism, species differences in the role played by other enzymes in a drug's metabolic clearance, and differences in systemic clearance mechanisms are critically important for the pharmacokinetic application of deuterium isotope effects. Ex vivo methods to project the in vivo outcome using deuterated carbazeran and zoniporide with hepatic systems demonstrate the importance of establishing the extent to which other metabolic enzymes contribute to the metabolic clearance mechanism. Differences in pharmacokinetic outcomes in guinea pig and rat, with the same metabolic clearance mechanism, show how species differences in the systemic clearance mechanism can affect the in vivo outcome. Overall, to gain from the application of deuteration as a strategy to alter drug pharmacokinetics, these studies demonstrate the importance of understanding the systemic clearance mechanism and knowing the identity of the metabolic enzymes involved, the extent to which they contribute to metabolic clearance, and the extent to which metabolism contributes to the systemic clearance.

[1]  R. Dempski,et al.  The Reductive Half-reaction of Xanthine Oxidase , 1999, The Journal of Biological Chemistry.

[2]  C. Beedham,et al.  Substrate specificity of human liver aldehyde oxidase toward substituted quinazolines and phthalazines: a comparison with hepatic enzyme from guinea pig, rabbit, and baboon. , 1995, Archives of biochemistry and biophysics.

[3]  A. B. Foster Deuterium isotope effects in studies of drug metabolism , 1984 .

[4]  F. Schneider,et al.  Enhanced Plasma Concentration by Selective Deuteration of Rofecoxib in Rats , 2006, Arzneimittelforschung.

[5]  R. Hanzlik,et al.  Kinetic deuterium isotope effects on the N-demethylation of tertiary amides by cytochrome P-450. , 1990, The Journal of biological chemistry.

[6]  R. Hanzlik,et al.  Deuterium isotope effects on toluene metabolism. Product release as a rate-limiting step in cytochrome P-450 catalysis. , 1989, Biochemical and biophysical research communications.

[7]  N. Vermeulen,et al.  Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: A study in healthy volunteers , 1988, Biopharmaceutics & drug disposition.

[8]  Editor-in-Chief R. Seifert,et al.  Naunyn-Schmiedeberg's archives of pharmacology , 2005, Klinische Wochenschrift.

[9]  R. Obach,et al.  Cross-Species Comparison of the Metabolism and Excretion of Zoniporide: Contribution of Aldehyde Oxidase to Interspecies Differences , 2010, Drug Metabolism and Disposition.

[10]  Deepak Dalvie,et al.  Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. , 2009, Chemical research in toxicology.

[11]  Bryan M. Li,et al.  Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. , 2009, Journal of medicinal chemistry.

[12]  A. Y. Lu,et al.  Kinetic isotope effects and ‘metabolic switching’ in cytochrome P450‐catalyzed reactions , 1987, BioEssays : news and reviews in molecular, cellular and developmental biology.

[13]  D. Kushner,et al.  Pharmacological uses and perspectives of heavy water and deuterated compounds. , 1999, Canadian journal of physiology and pharmacology.

[14]  F. Guengerich,et al.  Kinetics of Cytochrome P450 2E1-Catalyzed Oxidation of Ethanol to Acetic Acid via Acetaldehyde* , 1999, The Journal of Biological Chemistry.

[15]  T. Naruke,et al.  Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[16]  A. Boulton,et al.  Effect of chronic deuterated and non-deuterated phenelzine on rat brain monoamines and monoamine oxidase , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

[17]  J. Sahi,et al.  Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human. , 2008, Drug metabolism letters.

[18]  C. Beedham,et al.  Species variation in hepatic aldehyde oxidase activity , 1987, European Journal of Drug Metabolism and Pharmacokinetics.

[19]  J. Reid,et al.  A species difference in the presystemic metabolism of carbazeran in dog and man. , 1984, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  L. Pohl,et al.  Determination of toxic pathways of metabolism by deuterium substitution. , 1984, Drug metabolism reviews.

[21]  J. Cano,et al.  Human hepatocytes as a keyin vitro model to improve preclinical drug development , 1990, European Journal of Drug Metabolism and Pharmacokinetics.

[22]  W. Trager,et al.  The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[23]  B. Belleau,et al.  Effect of Deuterium Substitution in Sympathomimetic Amines on Adrenergic Responses , 1961, Science.

[24]  Y. Moriwaki,et al.  Immunohistochemical localization of aldehyde and xanthine oxidase in rat tissues using polyclonal antibodies , 2005, Histochemistry and Cell Biology.

[25]  Deepak Dalvie,et al.  Aldehyde oxidase: an enzyme of emerging importance in drug discovery. , 2010, Journal of medicinal chemistry.

[26]  M. Fratelli,et al.  Mammalian aldehyde oxidases: genetics, evolution and biochemistry , 2008, Cellular and Molecular Life Sciences.

[27]  J. Paxton,et al.  Inter-species variation in the metabolism and inhibition of N-[(2'-dimethylamino)ethyl]acridine-4-carboxamide (DACA) by aldehyde oxidase. , 2000, Biochemical pharmacology.

[28]  M. Monshouwer,et al.  In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor , 2011, The Pharmacogenomics Journal.

[29]  E. Pettersen,et al.  The bioavailability and dose dependency of the deuterated anti-tumour agent 4,6-benzylidene-d1-d-glucose in mice and rats , 2004, Cancer Chemotherapy and Pharmacology.

[30]  S. Kitamura,et al.  Drug-metabolizing ability of molybdenum hydroxylases. , 2006, Drug metabolism and pharmacokinetics.

[31]  S. Wrighton,et al.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[32]  Y. Moriwaki,et al.  Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. , 2001, Histology and histopathology.

[33]  M. Blake,et al.  EFFECTS OF DEUTERATION ON LOCOMOTOR ACTIVITY OF AMPHETAMINE , 1978 .

[34]  Jeffrey P. Jones,et al.  Studies on the mechanism of aldehyde oxidase and xanthine oxidase. , 2008, The Journal of organic chemistry.

[35]  F. Schneider,et al.  Changed Phosphodiesterase Selectivity and Enhanced in vitro Efficacy by Selective Deuteration of Sildenafil , 2007, Arzneimittelforschung.

[36]  C. Ioannides,et al.  Effect of deuteration of imipramine on its pharmacokinetic properties in the rat. , 1983, Biochemical pharmacology.

[37]  D. Newell,et al.  The metabolism of deuterated analogues of chlorambucil by the rat. , 1979, Chemico-biological interactions.